Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 91

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 91
---
 Transactions.” This information should be read together with OmnigenicsAI’s and SPAC’s financial statements and related notes, “ APx Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “ OmnigenicsAI Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other financial information included elsewhere in this proxy statement/prospectus. The unaudited pro forma combined consolidated financial information is presented for illustrative purposes only. Such information is only a summary and should be read in conjunction with the section titled “ Unaudited Pro Forma Combined Financial Information.” The financial results may have been different had the companies always been combined. You should not rely on the unaudited pro forma combined consolidated financial information as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the Combined Company will experience. The unaudited pro forma combined financial statements do not necessarily reflect what the Combined Company’s financial condition or results of operations would have been had the Business Combination occurred on said date. The unaudited pro forma combined financial information also may not be useful in predicting the future financial condition and results of operations of the Combined Company. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date of these unaudited pro forma combined financial information and are subject to change as additional information becomes available and analyses are performed. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. Such differences might include but are not limited to the estimated fair value of OmnigenicsAI equity consideration, the estimated fair value of Founder Shares and the exercise of redemption rights in respect of Public Shares. Rounding Certain figures (including percentage amounts) included in this pro forma combined consolidated financial information have been rounded for presentation purposes. Percentage figures and totals included in said pro forma information have, in some cases, been calculated based on such figures prior to rounding. For this reason, certain percentage and total amounts may vary from those obtained by performing the same calculations using the figures in the historical financial statements and figures shown as total in certain tables may not be an exact arithmetic aggregate of the other figures in such table. 18

The tables below should be read in conjunction with the accompanying notes to the unaudited pro forma condensed combined consolidated financial information. Combined Consolidated Statements of Operations for the year ended June 30, 2024
(In thousands of United States Dollars, except for per share data)

|                                                 |